U.S. markets close in 3 hours 41 minutes
  • S&P 500

    3,860.27
    +30.93 (+0.81%)
     
  • Dow 30

    31,306.81
    -95.20 (-0.30%)
     
  • Nasdaq

    13,367.62
    +248.19 (+1.89%)
     
  • Russell 2000

    2,215.05
    +14.88 (+0.68%)
     
  • Crude Oil

    62.35
    -1.18 (-1.86%)
     
  • Gold

    1,717.30
    -58.10 (-3.27%)
     
  • Silver

    26.24
    -1.44 (-5.22%)
     
  • EUR/USD

    1.2089
    -0.0097 (-0.80%)
     
  • 10-Yr Bond

    1.5010
    -0.0170 (-1.12%)
     
  • GBP/USD

    1.3956
    -0.0057 (-0.41%)
     
  • USD/JPY

    106.6550
    +0.4250 (+0.40%)
     
  • BTC-USD

    48,065.66
    -2,978.96 (-5.84%)
     
  • CMC Crypto 200

    963.72
    +30.58 (+3.28%)
     
  • FTSE 100

    6,483.43
    -168.53 (-2.53%)
     
  • Nikkei 225

    28,966.01
    -1,202.26 (-3.99%)
     

Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).

The Company granted stock options to purchase up to an aggregate of 8,000 shares of Kala Pharmaceuticals common stock to two new employees. The stock options were granted on April 15, 2020. The grant was approved by the Compensation Committee and was made as an inducement material to each employee entering into employment with Kala Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $9.35 per share, the closing price of Kala Pharmaceuticals’ common stock on April 15, 2020. The options have a ten-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee’s new hire date and the remainder vesting in equal monthly installments over the following three years. Vesting of each option is subject to such employee’s continued service with Kala Pharmaceuticals through the applicable vesting dates.

About Kala Pharmaceuticals, Inc.

Kala is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFYTM mucus penetrating particle Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in the January 2019 launch of INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% and its investigational product candidate, EYSUVISTM (loteprednol etabonate ophthalmic suspension) 0.25%, which is being studied for the treatment of the signs and symptoms of dry eye disease.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200417005015/en/

Contacts

Investors
Hannah Deresiewicz, 212-362-1200
Hannah.Deresiewicz@sternir.com